Patients With Lower-Stage Small-Cell Lung Cancer Do Better Patients With Lower-Stage Small-Cell Lung Cancer Do Better
Patients with stage I to II small-cell lung cancer (SCLC) treated with chemoradiotherapy have better outcome than those with stage III disease, according to a secondary analysis of a randomized clinical trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: World Pharma News)
Source: World Pharma News - December 6, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

Age Just a Number for Older, Fit Limited-Stage SCLC Patients
(MedPage Today) -- Standard chemoradiotherapy proved just as effective compared with younger patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 9, 2018 Category: Hematology Source Type: news

Concurrent chemo-radiotherapy should be a treatment option for elderly patients with LS-S
(International Association for the Study of Lung Cancer) Elderly patients with limited-stage small cell lung cancer (LS-SCLC) showed similar survival and toxicity compared to their younger counterparts when treated with concurrent chemo-radiotherapy. Concurrent chemo-radiotherapy should be a treatment option for fit patients aged 70 years or older. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2018 Category: Cancer & Oncology Source Type: news

Nanopore technology with DNA computing easily detects microRNA patterns of lung cancer
(Tokyo University of Agriculture and Technology) Researchers at Tokyo University of Agriculture and Technology (TUAT) have developed a simple technique that allows detection of two independent microRNAs as an early diagnosis marker of Small Cell Lung Cancer (SCLC) , which is very aggressive. In this technique, they combined nanopore and DNA computing technologies as rapid and label-free detection. This method, therefore, could help to identify SCLC in the early stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2018 Category: Cancer & Oncology Source Type: news

Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
The use of potent therapies inhibiting critical oncogenic pathways active in epithelial cancers has led to multiple resistance mechanisms, including the development of highly aggressive, small cell neuroendocrine carcinoma (SCNC). SCNC patients have a dismal prognosis due in part to a limited understanding of the molecular mechanisms driving this malignancy and the lack of effective treatments. Here, we demonstrate that a common set of defined oncogenic drivers reproducibly reprograms normal human prostate and lung epithelial cells to small cell prostate cancer (SCPC) and small cell lung cancer (SCLC), respectively. We ide...
Source: ScienceNOW - October 4, 2018 Category: Science Authors: Park, J. W., Lee, J. K., Sheu, K. M., Wang, L., Balanis, N. G., Nguyen, K., Smith, B. A., Cheng, C., Tsai, B. L., Cheng, D., Huang, J., Kurdistani, S. K., Graeber, T. G., Witte, O. N. Tags: Medicine, Diseases reports Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 25, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer FDA Approves Nivolumab (Opdivo) for Small Cell Lung Cancer
The new approval is accelerated and is therefore conditional upon further proof of efficacy, but the checkpoint inhibitor becomes the first approved option in advanced SCLC in a long time.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

BMS gets FDA ok for first new SCLC med in 20 years
Bristol-Myers Squibb announced that the U.S. FDA has approved Opdivo as a treatment for certain patients with previously treated small cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 17, 2018 Category: Pharmaceuticals Source Type: news

Researchers discover new vulnerability in deadly form of lung cancer
(UT Southwestern Medical Center) Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in small cell lung cancer (SCLC) that can be targeted by existing drug therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2018 Category: Cancer & Oncology Source Type: news

Researchers discover a new type of lung cancer
(Cold Spring Harbor Laboratory) Researchers have discovered a new kind of small-cell lung cancer (SCLC). The discovery paves the way for developing personalized medicine approaches to target this previously unnoticed form of the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2018 Category: Cancer & Oncology Source Type: news

PARP Inhibitor Active in SCLC Subgroup
(MedPage Today) -- Better OS seen among those expressing marker of DNA damage (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 23, 2018 Category: Hematology Source Type: news

PARP inhibitor improves overall response rates in small cell lung cancer patients
(University of Texas M. D. Anderson Cancer Center) In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients -- those whose tumors expressed SLFN11 -- who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 11, 2018 Category: International Medicine & Public Health Source Type: news

Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC
In this video,Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents. (Source: CancerNetwork)
Source: CancerNetwork - June 9, 2018 Category: Cancer & Oncology Authors: Apar Kishor Ganti, MD, MS Source Type: news

Targeting DNA Repair in SCLC and the Biomarker Landscape Targeting DNA Repair in SCLC and the Biomarker Landscape
Areas of investigation for SCLC include identification of predictive biomarkers, effective combinations to overcome resistance, and strategies for immunotherapy.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

New liquid biopsy-based cancer model reveals data on deadly lung cancer
(University of Texas M. D. Anderson Cancer Center) Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University of Texas MD Anderson Cancer Center offers a potential explanation for why the disease becomes chemoresistant, and a possible avenue to explore new diagnostic approaches. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Current Standards for Clinical Management of SCLC Current Standards for Clinical Management of SCLC
Review the latest on diagnosis, staging, and management of SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 15, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

PharmaMar's lurbinectedin ATLANTIS trial in SCLC will be an oral presentation
(Pharmamar) PharmaMar's lurbinectedin will have an oral presentation on small-cell lung cancer at the 18th annual meeting on Targeted Therapies in Lung Cancer that is organized by the International Association for the Study of Lung Cancer (IASLC), to be held in Santa Monica Feb. 21-24. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 20, 2018 Category: Cancer & Oncology Source Type: news

Pazopanib Improves PFS in Extensive-Disease SCLC, But Adds Toxicity
Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Clinical Utility of CTCs in Patients With SCLC Clinical Utility of CTCs in Patients With SCLC
Learn how CTCs can be diagnostic, prognostic, and predictive biomarkers in SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2018 Category: Consumer Health News Tags: None Journal Article Source Type: news

Many SCLC Patients Not Receiving Standard of Care Many SCLC Patients Not Receiving Standard of Care
A large proportion of limited-stage small cell lung cancer (SCLC) patients are not receiving standard-of-care treatment. One barrier appears to be coverage with Medicare/Medicaid.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

One in Five Limited-Stage SCLC Patients Get No Treatment (CME/CE)
(MedPage Today) -- Federally insured patients less likely to get radiation therapy (Source: MedPage Today Radiology)
Source: MedPage Today Radiology - January 5, 2018 Category: Radiology Source Type: news

Small-cell lung cancer patients face barriers to receiving standard-of-care treatment
(University of Texas M. D. Anderson Cancer Center) Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard-of-care for the initial management of non-metastatic small-cell lung cancer (SCLC), a large percentage of US patients do not receive these treatments and in turn have lower overall survival, according to research from The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2018 Category: International Medicine & Public Health Source Type: news

Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer
(International Association for the Study of Lung Cancer) Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. Dr. Li-Xu Yan of Guangdong General Hospital and Guangdong Academy of Medical Sciences in China presented her findings from this study today at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

New data on PM1183 sees a response rate of 36 percent as single agent in patients with SCLC
(Pharmamar) Up to today, there is only one approved therapy, topotecan, in relapsed disease, that offers a response rate of between 17 percent and 24 percent. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Anti-PD 1 Drug Active in Extensive SCLC (CME/CE)
(MedPage Today) -- Pembrolizumab provided 33% response rate in poor-prognosis disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 24, 2017 Category: Hematology Source Type: news

Study Finds That Proton-Beam Therapy is Safe for Treating an Aggressive Type of Lung Cancer
Proton-beam radiotherapy is safe and appears to be effective in treating some cases of small cell lung cancer (SCLC), an aggressive cancer that accounts for about 10 to 15 percent of all lung cancers, according to a new study published online in the journal Cancer. (Source: University of Maryland School of Medicine News Headlines)
Source: University of Maryland School of Medicine News Headlines - August 10, 2017 Category: Universities & Medical Training Source Type: news

Once-Daily RT Fails to Improve Over Standard in Limited-Stage SCLC
Once-daily RT given concurrently with chemotherapy showed no difference in survival compared with the twice-daily standard in small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Proton-Beam Therapy in Limited-Stage SCLC Shows Promising Efficacy
Proton-beam therapy was found to be safe for patients with limited-stage small-cell lung cancer in the first prospective registry study of the therapy, with only a small number of high-grade toxicities. (Source: CancerNetwork)
Source: CancerNetwork - July 10, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Radiation Oncology Source Type: news

Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival
Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Nivolumab Alone or With Ipilimumab Produced Durable Response in SCLC
Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Lung Cancer News Source Type: news

G-CSF Use in Small Cell Lung Cancer: New Data'Comforting'G-CSF Use in Small Cell Lung Cancer: New Data'Comforting '
Although patients with SCLC given granulocyte colony-stimulating factors during chemo-radiotherapy had an increased risk for hematologic complications, the drugs can be used safely, say researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

White blood cell boosting drugs safe during chemo-radiotherapy
New research shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 5, 2017 Category: Science Source Type: news

Study shows white blood cell boosting drugs safe during chemo-radiotherapy of lung cancer
(European Society for Medical Oncology) A late breaking subanalysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer (SCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2017 Category: Global & Universal Source Type: news

Bevacizumab Fails to Boost SCLC Survival (CME/CE)
(MedPage Today) -- PFS but not OS improved by angiogenesis inhibitor (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 26, 2017 Category: Hematology Source Type: news

Medical News Today: Small cell lung cancer: Symptoms, treatment, and outlook
What is small cell lung cancer and what are the causes and associated risk factors? How is SCLC diagnosed and what are the different stages? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2017 Category: Consumer Health News Tags: Lung Cancer Source Type: news

Prophylactic Cranial Irradiation Improved Survival in Metastatic SCLC
This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases. (Source: CancerNetwork)
Source: CancerNetwork - March 18, 2017 Category: Cancer & Oncology Authors: Sonam Sharma, MD Tags: Videos Lung Cancer Source Type: news

Prevention and prediction: Understanding how lung cancer progresses
(University of Pennsylvania School of Medicine) Treating the brain with a preventative course of radiation may help small cell lung cancer (SCLC) patients -- whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. A separate study revealed that the most commonly-targeted mutation of non-small cell lung cancer (NSCLC) is most likely to result in progression at the primary site. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 16, 2017 Category: Cancer & Oncology Source Type: news

Bevacizumab Combination Improves PFS, but Not OS, in Extensive-Disease SCLC
The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 30, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer News Source Type: news

Exceptional SCLC Survivors: 5-Year Median Survival Exceptional SCLC Survivors: 5-Year Median Survival
Longer-term survival of patients with extensive small cell lung cancer (SCLC) is associated with comprehensive cisplatin chemotherapy with additional chest and cranial radiation, suggest researchers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 20, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

G1 Therapeutics and Genentech to evaluate Phase II lung cancer trial of tecentriq and trilaciclib
US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy. (Source: Drug Development Technology)
Source: Drug Development Technology - December 7, 2016 Category: Pharmaceuticals Source Type: news

Updated KEYTRUDA ® (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat CancersKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA® (pembrolizumab), the company ’s anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer...
Source: Merck.com - Product News - December 6, 2016 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD NYSE:MRK Source Type: news

Histopathological Transformation to SCLC in NSCLC Tumors Histopathological Transformation to SCLC in NSCLC Tumors
Is it time to re-biopsy? Deterioration during targeted therapy may indicate transformation of NSCLC to SCLC.Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Blood test could predict best treatment for lung cancer
A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 21, 2016 Category: Science Source Type: news

Pearls from: Hossein Borghaei, DO
(MedPage Today) -- Thoracic oncologist discusses turning the corner in SCLC therapies (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - September 29, 2016 Category: Primary Care Source Type: news

Yervoy Plus Chemo Disappoints in SCLC (CME/CE)
(MedPage Today) -- Combo treatment did not prolong survival versus chemo alone in extensive-stage disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 7, 2016 Category: Hematology Source Type: news